Why Is Enochian BioSciences (ENOB) Stock Surging Today?

The FDA has accepted Enochian BioSciences Inc's ENOB pre-IND (Investigational New Drug) request for a potential functional cure or treatment of HIV.
Written comments are expected this Fall.
The request was based on the results of a 54-year old man living with HIV who had failed to suppress the virus with antiviral therapy.
The patient subsequently achieved viral control for 255 days with an innovative treatment of Natural Killer (NK) and Gamma Delta T-cells (GDT) collected from another person. During the entire period, no antiviral drugs were given.
It is believed that the GDT cells, a small subset of immune cells that can be infected with HIV, could be a critical factor in controlling the virus.
The company holds the exclusive license for the proprietary technology.
The Pre-IND submission requested that this strategy be extended to persons with HIV who have successfully suppressed the virus with antiviral treatment.
The findings were presented during the Conference of the American Society of Gene and Cell Therapy.
Price Action: ENOB shares are up 139% at $10.54 during the premarket session on the last check Monday.